Primary Menu

Randomized study of Vidaza for the treatment of patients with high-risk MDS.

The application is based on clinical data which include the results from the Company's Phase 3 multi-center, international, randomized study of Vidaza for the treatment of patients with high-risk MDS. Ctive of this Phase 3 study was the superiority in overall survival of Vidaza compared to conventional care regimens, and these data were presented at the American Society of Hematology in December 2007.

Important SafetyVidaza is contraindicated in patients with a known hypersensitivity to azacitidine or mannitol and in patients with advanced malignant hepatic tumors.In clinical trials the most common adverse reactions by SC route nausea were and ecchymosis and malaise , and hypokalemia (31.Take Care of Health System encourages all the patients, home health care, a primary health care provider they see for ongoing medical needs and offer routine investigation. If a patient's condition is outside the scope of service for a Take Care of Clinic, of in a suitable location to a suitable place for care, a primary health care provider and specialist.